Array BioPharma’s (ARRY) announcement yesterday (Saturday) of a plan to study its Braf/Mek inhibitor combination, encorafenib and binimetinib, in a poor performing sub-population of colorectal ...

Array Biopharma Inc (NASDAQ: ARRY) investors are jumping for joy after hearing the good news that the FDA is taking the drug maker's one-two combination punch of binimetinib (bini) and encorafenib ...

Susan Harkins shows you two easy ways to populate an Excel UserForm, and neither requires a single bit of VBA code.

Shares of Array Biopharma Inc. (NASDAQ:ARRY) climbed 81 percent to close at $6.61 on Monday after the Boulder, Colo.-based company announced that the first part of its phase III COLUMBUS trial in BRAF ...

Array BioPharma Inc. 's (NASDAQ: ARRY) shares increased more than 15% on Feb 6 after it announced encouraging overall survival (OS) data from a pivotal phase III study evaluating COMBO450, a ...

May 21 (Reuters) - Array BioPharma Inc's cocktailof three therapies helped patients with a type of colorectalcancer live longer than those on standard treatment, accordingto interim results of a ...